WMJ Vol 123 Issue 4: Multiple Lactobacillus Infections Caused by Probiotics at Pediatric and Adult Academic Medical Centers
ABSTRACT
Background: Probiotics are synthetic oral supplements containing live bacterial and fungal species hypothesized to help with various gastrointestinal conditions. However, they can cause infection if the organism spreads outside of the gastrointestinal tract. The aim of this study was to identify and describe patients who experienced systemic infections caused by probiotic use.
Methods: This study was a retrospective chart review of pediatric and adult patients at academic medical centers who received probiotics and subsequently developed positive cultures from a sterile site for probiotic-related species. Two individuals completed the chart reviews to determine if the probiotic was the true cause of the infection.
Results: Lactobacillus, Bifidobacterium, and Saccharomyces cultures were reviewed, with a total of 71, 8, and 2 cultures isolated from sterile sites for each organism, respectively. Further review revealed 23 Lactobacillus cultures from 13 unique patients who were taking Lactobacillus-containing probiotics. Four patients without gastrointestinal tract compromise were included in the final analysis, including 1 patient whose culture was confirmed as identical to the probiotic. Types of infections included meningitis and bacteremia. Targeted antimicrobial therapy included ampicillin, ampicillin-sulbactam, and piperacillin-tazobactam, with total durations of therapy ranging from 10 to 22 days. No patients had mortality attributed to Lactobacillus infection.
Conclusions: Probiotics are not harmless supplements as they come with risk of serious infection as demonstrated in this review. Before use, the risks of probiotics should be considered carefully for each individual patient. Clinicians should consider avoiding probiotics in hospitalized patients, especially those with vascular or extra-ventricular access devices.
Intended Audience
The intended audience for this continuing education activity is healthcare professionals caring for the people of Wisconsin and beyond.
Learning Objectives
As a result of participating in this journal-based activity, healthcare team members will be able to:
- Identify the risks associated with probiotic use
- Summarize the study findings regarding meningitis and bacteremia caused by probiotic-related species in pediatric and adult patients who received probiotics
- Enhance clinical decision-making regarding probiotic use
FACULTY DISCLOSURE
It is the policy of the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) to identify, mitigate and disclose all relevant financial relationships with ineligible companies* held by the speakers/presenters, authors, planners, and other persons who may influence content of this accredited continuing education (CE). In addition, speakers, presenters and authors must disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation.
For this accredited continuing education activity all relevant financial relationships have been mitigated and detailed disclosures are listed below.
Name of Individual | Individual's Role in Activity | Financial Relationship Disclosure | Discussion of Unlabeled/Unapproved Uses of Drugs/Devices |
Marianna Shershneva, MD, PhD | Accreditation Specialist | No relevant relationships with ineligible companies to disclose | No |
James Eberhard, MFA | Accreditation Specialist | No relevant relationships with ineligible companies to disclose | No |
Allison M. Samuel, PharmD | Author | No relevant relationships with ineligible companies to disclose | No |
Matthew G. Lammers, MD | Author | No relevant relationships with ineligible companies to disclose | No |
Joshua Nachreiner, PharmD | Author | No relevant relationships with ineligible companies to disclose | No |
Monica C. Bogenschutz, PharmD | Author | No relevant relationships with ineligible companies to disclose | No |
Kirsten Koffarnus, MS, RN, CPNP | Author | No relevant relationships with ineligible companies to disclose | No |
Lucas Schulz, PharmD | Author | No relevant relationships with ineligible companies to disclose | No |
Kristin A. Shadman, MD | Author | No relevant relationships with ineligible companies to disclose | No |
Joseph A. McBride, MD | Author | No relevant relationships with ineligible companies to disclose | No |
George Lee Morris III, M.D., MPH DIC | Reviewer | No relevant relationships with ineligible companies to disclose | No |
Alexis Waters, PA-C | Reviewer | No relevant relationships with ineligible companies to disclose | No |
Fahad Aziz MD | Editor | No relevant relationships with ineligible companies to disclose | No |
David Dwyer, PhD, RN, NEBC | Reviewer | No relevant relationships with ineligible companies to disclose | No |
Jennifer Esch, PharmD, MBA, BCPS | Reviewer | No relevant relationships with ineligible companies to disclose | No |
Cassie Meffert, PAC, MPH | Reviewer | No relevant relationships with ineligible companies to disclose | No |
*Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on, patients.
The ACCME does not consider providers of clinical services directly to patients to be ineligible companies.
Accreditation
Accreditation Logos | Accreditation Statements |
![]() | In support of improving patient care, this activity has been planned and implemented by the University of Wisconsin–Madison ICEP and the Wisconsin Medical Journal. The University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Credit Designation Statements
American Medical Association (AMA)
The University of Wisconsin–Madison ICEP designates this journal-based CE activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center (ANCC)
The University of Wisconsin–Madison ICEP designates this journal-based CE activity for a maximum of 1.0 ANCC contact hour.
American Academy of Physician Assistants (AAPA)
![]() | The University of Wisconsin–Madison ICEP has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 05/21/2026. PAs should only claim credit commensurate with the extent of their participation. |
Accreditation Council for Pharmacy Education (ACPE)
The University of Wisconsin–Madison ICEP designates this knowledge-based activity for 1.0 hours or 0.1 CEUs. Credit can be earned by successfully completing the activity and the evaluation. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion. UAN: JA0000358-9999-25-043-H01-P
Continuing Education Units
The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for 0.1 continuing education units (CEUs) or 1 hour.
Available Credit
- 1.00 AAPA Category 1 CME
- 1.00 ACPE Contact Hours - Pharmacist
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC Contact Hours
- 1.00 University of Wisconsin–Madison Continuing Education Hours
- 1.00 Approved for AMA PRA Category 1 Credit™
Accessibility
If you need anything to participate in this program, please contact [email protected].
Required Hardware/software
Free, current version of Chrome, Firefox, Safari, or Edge. Some older browsers and Microsoft Internet Explorer could produce error messages or not display the content correctly.
Free, current version of Adobe Acrobat Reader or other .pdf reader.